EUCRISA can be applied to the skin anywhere on the face and body1

EUCRISA is for topical use only and not for ophthalmic, oral, or intravaginal use1

No limitations on duration of use1

If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy

EUCRISA was studied in pivotal trials for 29 days and in an open-label safety extension study for up to 48 weeks

Studied as monotherapy in treatment-naïve and treatment-experienced patients2*

* Patients involved in pivotal trials were not required to have received prior treatment for atopic dermatitis. Those who did went through a washout period before starting treatment with EUCRISA.2

Mean BSA of 18.3% in pivotal trials2

Can be used on all skin tones2

Back to top

References

  1. EUCRISA® (crisaborole) Full Prescribing Information. December 2018.
  2. Data on file. Pfizer Inc., New York, NY.
  3. Eichenfield LF, et al. J Am Acad Dermatol. 2017;77(4):641-649.